sponsored
PatientsVille.com Logo

PatientsVille

Cdp870 Medical Research Studies

Up-to-date List of Cdp870 Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cdp870 Medical Research Studies

Rank Status Study
1 Recruiting Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500;   Drug: rituximab
Outcome Measures: PK (Part I only): AUC0-tz (area under the plasma concentration versus time curve from time zero to the last measurable concentration, determined over both dosages);   The proportion of patients meeting the ACR20 (American College of Rheumatology 20% response criteria);   Change from Baseline in DAS28-ESR (Disease Activity Score 28-erythrocyte sedimentation rate);   PK (Part I only): AUC0-inf pred (area under the plasma concentration versus time curve from time zero to infinity, over both dosages;   PK (Part I only): AUC0-336 (area under the plasma concentration versus time curve from time zero to 336 hours);   PK (Part I only): observed Cmax (maximum plasma concentration, determined after the second drug infusion);   PK (Part I only): AUC0-inf, ppk, determined over both dosages;   The proportion of patients meeting the ACR50 (American College of Rheumatology 50% response criteria);   The proportion of patients meeting the ACR70 (American College of Rheumatology 70% response criteria);   The proportion of patients meeting the ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) definition of remission;   Change from Baseline in DAS28-CRP (Disease Activity Score 28-C-reactive protein);   European League Against Rheumatism (EULAR) response (good, moderate, no response);   Patient´s global assessment of disease activity;   Physician´s global assessment of disease activity;   Change from Baseline in 36-item Short Form Health Survey (SF-36);   Immunogenicity (proportion of patients with anti-drug antibodies);   Swollen joint count;   Tender joint count;   Patient´s assessment of pain;   Health Assessment Questionnaire - Disability Index (HAQ-DI);   Acute phase reactant C-reactive protein (CRP)
2 Recruiting Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout
Condition: Chronic Gout
Intervention: Biological: pegloticase
Outcome Measures: Number of participants with pre-specified adverse events;   Serum uric acid response;   Change from Baseline in Number of Swollen Joints at 25 weeks;   Change from Baseline in Number of Swollen Joints at 51 weeks;   Change from Baseline in Number of Tender Joints at 25 weeks;   Change from Baseline in Number of Tender Joints at 51 weeks;   Change from Baseline in Number of Tophi at 25 weeks;   Change from Baseline in Number of Tophi at 51 weeks;   Change from Baseline in Number of Swollen Joints at Early Discontinuation;   Change from Baseline in Number of Tender Joints at Early Discontinuation;   Change from Baseline in Number of Tophi at Early Discontinuation;   Change from Baseline in Number of Gout Flares at 6 weeks;   Change from Baseline in Number of Gout Flares in weeks 6-12;   Change from Baseline in Number of Gout Flares in Months 3-6;   Change from Baseline in Number of Gout Flares in Months 6-9;   Change from Baseline in Number of Gout Flares in Months 9-12;   Change from Baseline in Number of Gout Flares in Months 12-15
3 Recruiting An Open-label Extension Study Evaluating the Safety and Efficacy of ABT-494 in Rheumatoid Arthritis Subjects
Condition: Rheumatoid Arthritis
Intervention: Drug: ABT-494
Outcome Measures: American College Rheumatology (ACR) 20 Response Rate;   ACR 50 Response Rate;   ACR 70 Response Rate;   Change in Tender Joint Count;   Change in Swollen Joint Count;   Change in Patient's Assessment of Pain;   Change in Patient's Global Assessment of Disease Activity;   Change in High-Sensitivity C-Reactive Protein (hsCRP);   Change in Health Assessment Questionnaire Disability Index;   Proportion of subjects achieving Low Disease Activity;   Proportion of subjects achieving Clinical Remission;   Change in DAS28 [CRP];   Change in CDAI;   Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale;   Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS);   Change in EQ-5D;   Incidence of Adverse Events;   Change in Vital Signs;   Change in Physical Examination;   Change in Clinical Laboratory Data
4 Recruiting Rituximab in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Rituximab;   Drug: Placebo (NaCl)
Outcome Measures: Number of tender and swollen joints;   Quality of life: SSc-HAQ;   Scleroderma;   Lung fibrosis;   Quality of life: SF-36;   Quality of life:  Duruöz index
5 Recruiting An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
Condition: Rheumatoid Arthritis
Intervention: Drug: Certolizumab Pegol
Outcome Measures: Percentage of subjects that withdrew due to a Treatment-emergent Adverse Event (TEAE);   Percentage of subjects with at least one Treatment-emergent Adverse Event (TEAE);   Percentage of subjects with at least one Treatment-emergent Serious Adverse Event (SAE);   Percentage of subjects meeting the American College of Rheumatology 20 (ACR20) in relation to Baseline;   Percentage of subjects meeting the American College of Rheumatology 50 (ACR50) in relation to Baseline;   Percentage of subjects meeting the American College of Rheumatology 70 (ACR70) in relation to Baseline;   Change from Baseline value in duration of morning stiffness;   Change from Baseline value in tender joint count;   Change from Baseline value in swollen joint count;   Change from Baseline value in Physician's Global Assessment of Disease Activity (PhGADA);   Change from Baseline value in Patient's Assessment of Arthritis Pain (PtAAP);   Change from Baseline value in Patient's Global Assessment of Disease Activity (PtGADA);   Change from Baseline value in Health Assessment Questionnaire-Disability Index (HAQ-DI);   Change from Baseline in Disease Activity Score 28 Joint Count Erythrocyte Sedimentation Rate (DAS28(ESR));   Percentage of subjects who achieve Disease Activity Score 28 Joint Count Erythrocyte Sedimentation Rate (DAS28(ESR)) remission
6 Recruiting Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
Condition: Moderate to Severe Rheumatoid Arthritis
Intervention: Biological: etanercept
Outcome Measures: To evaluate the efficacy of etanercept in adult subjects with moderate to severe rheumatoid arthritis who failed to respond or responded and then lost response to adalimumab as first biologic agent.;   Determine if anti-adalimumab antibodies predict response to etanercept, to determine if adalimumab failures predict response to etanercept, and to evaluate the effects of etanercept
7 Recruiting A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
Outcome Measures: Change in disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR);   Change in ACR/EULAR response;   Change in disease activity (CDAI/SDAI);   Change in joint swelling/tenderness (SJC/TJC);   Incidence of adverse events;   Changes in ultrasound assessment of joint inflammation (synovitis ultrasound scoring system);   Incidence of anti-therapeutic antibodies
8 Recruiting A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
Outcome Measures: Efficacy: Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) Remission Rate;   Safety: Incidence of adverse events (AE);   Efficacy: Change in DAS28-ESR;   Efficacy: ACR/EULAR responses;   Efficacy: Change in disease activity (CDAI/SDAI);   Efficacy: Change in Joint Swelling/tenderness (SJC/TJC);   Safety: Assessment of immunogenicity;   Patient-reported outcomes;   Efficacy: DAS28-ESR Remission Rate;   Efficacy: Proportion of patients who maintain DAS28 Remission/LDA;   Safety: Rates of AE leading to dose modification or study withdrawal;   Safety: Assessment of physical examination and vital signs;   Safety: Incidence of clinically significant laboratory abnormalities following treatment
9 Recruiting The Safety and Efficacy of RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rheumatoid Arthritis Patients.
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
Outcome Measures: Safety: Incidence of adverse events;   Safety: Health assessment;   Safety: Assessment of immunogenicity;   Efficacy: Change in DAS28-ESR;   Efficacy: ACR/EULAR responses;   Efficacy: Change in disease activity (CDAI/SDAI);   Efficacy: Change in Joint Swelling/tenderness (SJC/TJC)
10 Recruiting Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
Condition: Rheumatoid Arthritis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
Outcome Measure: Tender joint count;Swollen joint count; Patient's global assessment of disease;Patient's assessment of pain;Patient's assessment of physical activity; (Health Assessment Questionnaire [HAQ]); Acute phase reactant value (erythrocyte sedimentation rate).
11 Recruiting Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention:
Outcome Measures: Number of missed working days; self assessed workability; severity of clinical symptoms (number of tender and swollen joints), C-reactive Protein; severity of functional impairment; assessment of quality of life. Safety: Analysis of adverse events.;   Number and duration of hospitalization; number of days of impairment of non-professional activities; self-assessment of therapy in comparison to previous therapies.
12 Recruiting The Norwegian Antirheumatic Drug Register
Condition: Inflammatory Joint Diseases
Intervention:
Outcome Measures: Disease Activity Score-28 (DAS28);   American College of Rheumatology (ACR) responses (ACR20, ACR50, ACR70);   Simplified Disease Activity Index (SDAI);   American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission;   Ankylosing Spondylitis Disease Activity Score (ASDAS);   Assessments of Spondyloarthritis International Society (ASAS) responses (ASAS20, ASAS40);   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Modified Health Assessment Questionnaire (MHAQ);   Rheumatoid Arthritis Impact of Disease (RAID);   Work Productivity and Activity Impairment (WPAI) Questionnaire;   EuroQol 5-dimensions (EQ-5D) questionnaire;   28-Swollen joint count;   28-Tender joint count;   Erythrocyte Sedimentation Rate (ESR);   C-Reactive Protein (CRP);   Sharp/van der Heijde score;   Number of participants with adverse events;   Clinical Disease Activity Index (CDAI)
13 Unknown  A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.
Condition: Arthritis, Rheumatoid
Intervention: Other: Questionnaire
Outcome Measures: The validity of the questionnaire FLARE.;   The discriminating power of the instrument FLARE.;   The feasibility of the questionnaire FLARE
14 Unknown  Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: rituximab
Outcome Measures: Evaluation in week 24 and until study end: ASAS 20 in AS patients naïve to TNFalpha inhibitors as well as in AS patients with previous therapy with TNFalpha inhibitors.;   Safety Evaluations (Adverse events, vital signs, physical examination results, and clinical laboratory values until week 48);   Efficacy Evaluations:;   ASAS 40 response;   ASAS criteria for partial remission;   Duration of response;   BASDAI 20%, 50%, 70% improvement;   BASFI;   Mobility examinations;   BASMI;   Chest Wall Expansion;   disease controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6);   CRP, ESR;   Quality of Life;   SF-36Numeric Rating Scale (NRS);   physicians global;   patients global;   general pain;   nocturnal pain Enthesitis index (Maastricht scale;   swollen joint countEQ-5D;   Socio-economic questionnairecourse of change of active and chronic inflammatory lesions in MRI after 24 weeks and after 48 weeksB cell analysis and T cell analysis
15 Recruiting An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Drug: Tocilizumab (RoActemra/Actemra)
Outcome Measures: Absolute change in Genant-modified total Sharp score (mTSS);   Change in Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) remission (defined as DAS28<2.6);   Change in American College of Rheumatology (ACR20/50/70) response;   Change in European League Against Rheumatism (EULAR) Response;   Change in Simplified Disease Activity Index (SDAI);   Change in Clinical Disease Activity Index (CDAI);   Change in total tender joint count (TJC);   Change in swollen joint count (SJC);   Change in Patient Reported Outcomes;   Safety: Adverse events;   Safety: Assessment of immunogenicity;   Absolute change from baseline in rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS) scoring of erosions, synovitis, cartilage loss and osteitis.
16 Recruiting Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
Conditions: Diabetes Mellitus, Type 2;   Arthritis, Rheumatoid
Interventions: Drug: Anakinra;   Drug: TNF alpha inhibitors
Outcome Measures: Glycated Hemoglobin;   Percentage of patients in remission ( EULAR Criteria );   Percentage of patients improved ( EULAR criteria);   Count of tender joints (66 joints);   Count of swollen joints (68 joints);   Administration at Health Assessment Questionnaire ( HAQ);   C-reactive protein (CRP) and erythrocyte sedimentation rate ( ESR );   Plasma levels of glucose
17 Recruiting A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra/Actemra]
Outcome Measures: Long-term Safety: Incidence of adverse events;   Change in Disease Activity Index 28-Erythocyte Sedimentation Rate (DAS28-ESR);   Change in tender joint count (TJC);   Change in swollen joint count (SJC)
18 Unknown  Effects of Low Frequency Neuromuscular Electrical Stimulation Applied to the Quadriceps in the Production of Knee Extension Strength and Control of Edema After Anterior Cruciate Ligament Reconstruction
Condition: Athlete´s Knee
Interventions: Other: electrical stimulation;   Other: physical therapy exercises
Outcome Measure:
19 Recruiting Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency
Conditions: Rheumatoid Arthritis;   Vitamin D Deficiency
Intervention: Other: cholecalciferol versus placebo
Outcome Measures: The change in functional disability measured by the HAQ between the treated group and the placebo group.;   The EULAR response criteria;   ACR response criteria;   The number of tender joints;   The number of swollen joints;   VAS pain;   EVA activity;   Parameters of inflammation;   Asthenia collected by VAS and FACIT - tiredness;   The impact of RA activity (RAID);   Quality of life (SF-36, EMIR, MOS, PASS)
20 Recruiting Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Interventions: Drug: Thalidomide 150mg;   Drug: Thalidomide 100mg;   Drug: Placebo
Outcome Measures: Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20);   Change of ASDAS score;   Mean change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);   Mean change from baseline in Bath Ankylosing Spondylitis Function Index(BASFI);   Mean change from baseline in Nocturnal Pain using a Visual Analog Scale(VAS);   Mean change from baseline in back pain using a Visual Anolog Scale(VAS);   Morning stiffness;   Number of Peripheral swollen joints;   Number of Peripheral joint tenderness;   Chest expansion;   ESR;   CRP;   Schober test;   Scoliosis

These studies may lead to new treatments and are adding insight into Cdp870 etiology and treatment.

A major focus of Cdp870 research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cdp870